Answers are grounded in this paper and cite their sources.
Review explores the role of histamine and antihistamines in cancer progression and suggests improvements for immunotherapy.
Despite advances in treatment, cancer remains a leading cause of death worldwide. Immunotherapy has revolutionized clinical oncology, extending survival for many patients with advanced disease; however, low response rates in certain cancers remain a major challenge. Histamine, traditionally known as an inflammatory and allergic mediator, has recently been implicated in key aspects of cancer biology. Through binding to its receptors, histamine influences cancer cell proliferation, migration, invasion, apoptosis, and drug resistance. Furthermore, emerging evidence suggests that combining antihistamines with immunotherapeutic agents may improve patient survival. This review focuses on the roles of histamine and its receptors in modulating cancer progression and explores how antihistamines might interfere with these processes. We also discuss the significance of histamine within the tumor microenvironment and propose how modulating histamine signaling could enhance the efficacy of immunotherapy. These insights aim to guide the rational design of future chemo-immunotherapy combinations.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: